



HAL
open science

NanoPULSE: An Innovative Microfluidics-Based Active Mixer for Lipid Nanoparticle Formulation

Elio Gereige, Audrey Nsamela, Matthieu Kerhuel, Brice Calvignac, Marie Bonnin, Robin Oliveres, Thomas Guérinier

► **To cite this version:**

Elio Gereige, Audrey Nsamela, Matthieu Kerhuel, Brice Calvignac, Marie Bonnin, et al.. NanoPULSE: An Innovative Microfluidics-Based Active Mixer for Lipid Nanoparticle Formulation. CRS 2024 Annual Meeting and Exposition, Jul 2024, Bologne (ITA), France. hal-04723323

HAL Id: hal-04723323

<https://hal.science/hal-04723323v1>

Submitted on 7 Oct 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



NanoPULSE: An Innovative Microfluidics-Based Active Mixer for Lipid Nanoparticle Formulation

Elio Gereige^{a,b}, Audrey Nsamela^a, Matthieu Kerhuel^a, Brice Calvignac^b, Marie Bonnin^b, Robin Oliveres^a and Thomas Guérinier^a

^a InsideTx, Bordeaux, France

^b Univ Angers, Inserm, CNRS, MINT, SFR ICAT, F-49000 Angers, France

ABSTRACT: The field of nanomedicine has been attracting experts from various disciplines, aiming to develop nanocarriers capable of encapsulating potent drugs and nucleic acids to treat or prevent critical diseases, exemplified by RNA-LNP therapies. This progress has created a demand for tools that enables the precise synthesis of **monodisperse lipid nanoparticles (LNPs)**. However, **the field currently lacks a reliable method to scale production** from laboratory research (μL scale) to large-scale clinical production (10+L), hindering the translation from drug development to clinical application. Here, we introduce Nanopulse, a patented **microfluidic-based active micromixer prototype (NanoPULSE) leveraging Taylor-Aris Dispersion**, designed to meet this urgent manufacturing need in the pharmaceutical industry.

PROBLEMATIC :

- Small volume limitation:** large scale methods (IJM, T-mixer...) cannot be used at lab scale (< 1 mL).
- Quality issues:** microfluidic techniques fail after a limited production time due to agglomeration issues, leading to higher PDIs and rendering scale-up difficult.
- Scalability bottleneck:** traditional micromixing techniques rely on chaotic mixing, resulting in flow-rate-depending RNA-LNP characteristics.

1 Solution 1: Ensuring Low volume production

NanoPULSE is inspired by microfluidic systems and allows for highly controlled LNP synthesis at low volumes (<1 mL) for screening & preclinical development. This **highly scalable micromixer** is based on the **Taylor-Aris Dispersion** of sequentially injected fringes of fluids.





Figure 1. A) NanoPULSE prototype system and **B)** schematic of the working principle with footprints and minimal production volumes.


2 Solution 2: Maintaining constant COAs during scale up



HIGHLIGHTS

- NanoPULSE** is a unique active mixing technique allowing **continuous production** of RNA-LNP at both **low and high flow rates and volumes**.
- Experimental data show **constant size** over a 6-fold increase in flow rate and **high monodispersity** (PDI < 0.2).
- NanoPULSE has been proven to be **highly repeatable** and **100% agglomeration free** in the mixing channel even after long production times.

3 Solution 3: Allowing for Continuous production at large scale



CONCLUSIONS & PERSPECTIVES: NanoPULSE introduces a novel **active mixing technology** that enables **flow-rate-independent synthesis** through **high-frequency valve switching** using **Taylor-Aris dispersion**. This allows for **precise control** over small sample production **at the μL scale** and seamless transition to **continuous large-scale production**. The active mixing properties ensure the synthesis of nearly identical LNPs across various scales and flow rates. Future validation steps include increasing flow rates with higher valves frequencies, correlating Lagrangian simulation results with experimental data, and confirming the consistency of LNPs' critical attributes such as **zeta potential and encapsulation efficiency**. We also aim to validate the continuous, **agglomeration-free production** of liposomes at large scale. This would confirm NanoPULSE's capability to support all drug development stages, from sub-mL to large-scale continuous production, while ensuring scalability.

